MA71692A - Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique - Google Patents
Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémiqueInfo
- Publication number
- MA71692A MA71692A MA71692A MA71692A MA71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A MA 71692 A MA71692 A MA 71692A
- Authority
- MA
- Morocco
- Prior art keywords
- milvexian
- prevention
- treatment
- ischemic stroke
- ischemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370031P | 2022-08-01 | 2022-08-01 | |
| US202263401361P | 2022-08-26 | 2022-08-26 | |
| US202263379848P | 2022-10-17 | 2022-10-17 | |
| US202363498945P | 2023-04-28 | 2023-04-28 | |
| EP23761286.6A EP4565231A1 (fr) | 2022-08-01 | 2023-08-01 | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
| PCT/US2023/029178 WO2024030409A1 (fr) | 2022-08-01 | 2023-08-01 | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71692A true MA71692A (fr) | 2025-05-30 |
Family
ID=87801450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71692A MA71692A (fr) | 2022-08-01 | 2023-08-01 | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4565231A1 (fr) |
| JP (1) | JP2025525915A (fr) |
| KR (1) | KR20250043544A (fr) |
| CN (1) | CN119816305A (fr) |
| CA (1) | CA3263789A1 (fr) |
| CL (1) | CL2025000255A1 (fr) |
| IL (1) | IL318260A (fr) |
| MA (1) | MA71692A (fr) |
| MX (1) | MX2025000873A (fr) |
| TW (1) | TW202423444A (fr) |
| UY (1) | UY40381A (fr) |
| WO (1) | WO2024030409A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024257779A1 (en) * | 2023-04-19 | 2025-12-04 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome |
| AU2024258924A1 (en) * | 2023-04-19 | 2025-11-27 | Bristol-Myers Squibb Company | Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| BR112021020257A2 (pt) | 2019-04-11 | 2021-12-07 | Bristol Myers Squibb Co | Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico |
| CA3179957A1 (fr) | 2020-04-10 | 2021-10-14 | Bristol-Myers Squibb Company | (9r,135s)-13-{4-[5-chloro-2-(4-chloro-1h,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02·6]octadeca-1(18) ,2(6),4,14,16-pentaen-8-one |
| TW202229280A (zh) | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | (6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之製備方法 |
| EP4401736A1 (fr) * | 2021-09-17 | 2024-07-24 | Bristol-Myers Squibb Company | Milvexian pour la prévention et le traitement de troubles thromboemboliques |
-
2023
- 2023-08-01 CN CN202380056678.9A patent/CN119816305A/zh active Pending
- 2023-08-01 MA MA71692A patent/MA71692A/fr unknown
- 2023-08-01 KR KR1020257006915A patent/KR20250043544A/ko active Pending
- 2023-08-01 TW TW112128801A patent/TW202423444A/zh unknown
- 2023-08-01 IL IL318260A patent/IL318260A/en unknown
- 2023-08-01 WO PCT/US2023/029178 patent/WO2024030409A1/fr not_active Ceased
- 2023-08-01 JP JP2025506000A patent/JP2025525915A/ja active Pending
- 2023-08-01 UY UY0001040381A patent/UY40381A/es unknown
- 2023-08-01 CA CA3263789A patent/CA3263789A1/fr active Pending
- 2023-08-01 EP EP23761286.6A patent/EP4565231A1/fr active Pending
-
2025
- 2025-01-22 MX MX2025000873A patent/MX2025000873A/es unknown
- 2025-01-28 CL CL2025000255A patent/CL2025000255A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202423444A (zh) | 2024-06-16 |
| UY40381A (es) | 2024-01-31 |
| CL2025000255A1 (es) | 2025-06-13 |
| MX2025000873A (es) | 2025-03-07 |
| KR20250043544A (ko) | 2025-03-28 |
| WO2024030409A1 (fr) | 2024-02-08 |
| CA3263789A1 (fr) | 2024-02-08 |
| EP4565231A1 (fr) | 2025-06-11 |
| IL318260A (en) | 2025-03-01 |
| CN119816305A (zh) | 2025-04-11 |
| JP2025525915A (ja) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71692A (fr) | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique | |
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| EP4221604A4 (fr) | Dispositifs intravasculaires de limitation d'écoulement pour le traitement d'un ?dème | |
| EP4058037A4 (fr) | Thérapie à base de fibroblastes pour le traitement et la prévention d'un accident vasculaire cérébral | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA50073A (fr) | Polythérapie de lasmiditan et d'un antagoniste du cgrp pour une utilisation dans le traitement de la migraine | |
| EP4157324A4 (fr) | Analogue de pth pour le traitement de l'hypoparathyroïdie | |
| EP3927706A4 (fr) | Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs | |
| EP4366720A4 (fr) | Utilisation de bêta-hydroxybutyrates pour le traitement ou la prévention d'anévrismes et de dissections | |
| EP3968989A4 (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
| EP3876967A4 (fr) | Microbiote thérapeutique pour le traitement et/ou la prévention d'une dysbiose | |
| EP4297868A4 (fr) | Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer | |
| EP4157341A4 (fr) | Peptides pour la prévention et le traitement de la covid-19 | |
| EP3931178A4 (fr) | Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire | |
| EP3777848A4 (fr) | Composition pour la prévention ou le traitement d'un accident vasculaire cérébral | |
| EP3936124A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques | |
| EP3883552A4 (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3785718A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une maladie infectieuse de flavivirus | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| EP4127233A4 (fr) | Dosages pour la détection d'agents pathogènes | |
| EP4232075A4 (fr) | Composés, compositions et méthodes d'utilisation pour le traitement de spondylodèses | |
| EP4238561A4 (fr) | Utilisation de zanamivir dans la préparation d'un médicament pour le traitement ou la prévention de la prééclampsie | |
| EP4230652A4 (fr) | Anticorps anti-oscar pour la prévention ou le traitement de l'arthrose | |
| EP4349341A4 (fr) | Préparation pharmaceutique pour la prévention ou le traitement de la fibrose pulmonaire | |
| EP4185304A4 (fr) | Hydrogel thérapeutique pour l'administration de lymphocytes t car |